RxDoctor Payments Data

Bharat Allam, DO

Internal Medicine · Montclair, NJNPI 1780001891

Payments from drug & device makers

$662in general payments, 2019–2025

Across 15 payments — averaging $44.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$299
  • Medtronic$142
  • Exact Sciences$111
  • Lilly USA, LLC$32
  • Novo Nordisk$19
  • Dexcom, Inc.$18
  • plus $41 from 3 others

What the payments were for

  • Food & beverage$65198%
  • Education$112%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott2$299
Medtronic1$142
Exact Sciences5$111
Lilly USA, LLC2$32
Novo Nordisk1$19
Dexcom, Inc.1$18
GSK1$17
Novartis1$13
Amgen1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$662 in reported general payments places this provider in the 60th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$417,963
Medicare patients
549
Services billed
3,278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban186$100,859
JardianceEmpagliflozin33$44,046
OzempicSemaglutide14$24,560
EntrestoSacubitril/Valsartan28$23,619
XareltoRivaroxaban99$23,525
TrulicityDulaglutide83$21,913
TradjentaLinagliptin51$15,469
CreonLipase/Protease/Amylase59$9,635
JanumetSitagliptin Phos/Metformin Hcl14$8,560
FarxigaDapagliflozin Propanediol15$7,688
SantylCollagenase Clostridium Hist.19$6,624
Divalproex Sodium117$6,555
Atorvastatin Calcium724$6,085
Levothyroxine Sodium271$3,856
Metoprolol Succinate421$3,728

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$19$24,56014 claims
NovartisEntresto$13$23,61928 claims
Lilly USA, LLCTrulicity$32$21,91383 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Montclair

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →